Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal swab could curb unnecessary antibiotics in pneumonia

NCT ID NCT03586362

Disease control Sponsor: CAMC Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether a negative MRSA nasal swab can safely guide doctors to stop vancomycin earlier in adults hospitalized with pneumonia. Participants receive standard antibiotics, but vancomycin is either continued or stopped based on the swab result. The goal is to see if stopping vancomycin leads to similar clinical improvement while reducing side effects like kidney injury.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vancomycin de-escalation guided by MRSA nasal swab
What this could lead to
If successful, this approach could reduce unnecessary antibiotic use, lower the risk of kidney injury, and shorten hospital stays for pneumonia patients.
What could go wrong
The trial is non-inferiority, meaning it checks if stopping vancomycin is not worse than continuing it. Results may vary, and there's a small risk of missing a true MRSA infection despite a negative swab.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

278 people

The number who actually took part.

Started

Feb 2018

Finished

Sep 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients admitted to Charleston Area Medical Center through the Emergency Department with a diagnosis of pneumonia will be evaluated for potential enrollment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 18 years old * Patients admitted to Charleston Area Medical Center (CAMC) through the Emergency Department who meet the CDC criteria for pneumonia. * Nasal surveillance culture for MRSA obtained in the Emergency Department * Patients receiving vancomycin and additional antibiotic therapy for gram-negative coverage Exclusion Criteria: * Persistent vasopressor requirements when MRSA nasal swab results are available * Patients not meeting the CDC criteria for pneumonia * Patients presenting to the ED with leukopenia (≤4000) without previous documentation of normal or elevated WBC * Patients receiving empiric MRSA antibiotic therapy other than vancomycin for pneumonia * Patients with the diagnosis of lung abscess * Patients not receiving vancomycin therapy before MRSA nasal swab results are reported * Immunocompromised individuals. i.e. patients with AIDS/HIV, vasculitis on immune suppressor therapy, steroid therapy for more than one week prior admission or who received chemotherapy in the last 3 months * Patients who do not have a MRSA nasal swab obtained in the ED * Nares swab obtained after the completion of the first administered dose of an antibiotic with activity against MRSA * Patients with MRSA bacteremia * Patients with chronic tracheostomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumonia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumonia

Contacts and locations

Locations

  • Charleston Area Medical Center

    Charleston, West Virginia, 25304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.